kidney transplantation between HL-A identical unrelated individuals and the difficulty of establishing a statistically significant correlation between HL-A matching grade and clinical outcome of the graft (Stewart et al., 1970) indicate that the observations in siblings cannot be directly transposed to the unrelated situation. If the HL-A locus, as currently defined by two segregant series, is not solely responsible for mixed lymphocyte culture reactivity the additional factors responsible for this reactivity may also contribute to histocompatibility and be relevant to transplantation. Elucidation of these factors could help us to define histoidentity more precisely and then the results of transplantation with unrelated cadaveric donors may more closely approach the excellent results of HL-A identical sibling transplants.
Introduction
A large body of opinion holds that human tumours, like experimental animal tumours, possess tumour-specific antigens (tumour neoantigens) (Fairley, 1969 (Fairley, , 1970 Mathe, 1969 Mathe, , 1970 Alexander, 1970; Klein, 1970; Woodruff, 1970 ). Yet only in a minority of cancer patients have antibody responses to tumour neoantigens been detected (Graham and Graham, 1955; Wilson et al., 1963; Southam, 1965; Dore et al., 1967; Lewis, 1967; Lewis et al., 1969) .
In a previous communication from this department, Hodkinson and Taylor (1969) reported the detection of tumourspecific antibodies in the sera of only 2 out of 34 cases of human carcinoma. One reason suggested for the low frequency of tumour antibody detection was the possibility that while the tumour is in situ a slow constant release of tumour antigen combines with any antibody produced so that the latter is not detectable in the serum. The work reported here is an investigation of this possibility, and the findings suggest that reaction in vivo between tumour neoantigens and tumour antibodies could be a reason for the low frequency of antibody detection.
Materials and Methods
Tumour and corresponding normal tissues from the same individual were obtained from surgical specimens within half were tested by immunofluorescence, complement fixation, passive haemagglutination, and precipitation techniques against autologous sera in attempts to detect tumour-specific antibodies. The preparation of cellular fractions from tumour and normal tissue specimens, the preparation of serum, and the serological techniques used have been fully described elsewhere (Hodkinson and Taylor, 1969; Taylor and Odili, 1970) . Tissue specimens, sera, and tissue fractions were stored at -25°C until required. Tissues and sera from 36 patients were studied.
Results
Tumour-specific antibody responses were detected in 5 (140o) of the 36 cancer patients studied (Table 1 ). In four of the five positive cases the autologous sera reacted against the nuclear fraction of the tumours; in the fifth case the serum reactivity was directed against the microsomal fraction. Complement fixation was by far the best method of antibody detection.
The positive sera in all five cases gave negative tests against the corresponding autologous normal tissue fractions-that is, the antibodies were strictly tumour specific. All sera giving positive results were retested at least three times against both tumour and corresponding normal tissue fractions and consistent results were obtained. Another possible reason for the rise in titre of tumour antibody and its improved detection after tumour removal is the fact that manipulation of tumours at operation may lead to release of live tumour cells into the circulation, and the neoantigens of the released tumour cells could act as further stimulus for antibody production. Since most malignant tumours undergo some degree of necrosis, implying that intracellular antigens are released, it may be that neoantigens from necrotic tumour cells are not as immunogenic as those of live or whole tumour cells. The demonstration by Ikonopisov et al. (1970) , that of 13 patients with malignant melanoma in whom antibodies were not detectable the subcutaneous injection of irradiated autologous tumour cells resulted in the development of tumour antibodies in nine, may be supportive evidence for this suggestion. In the cases reported by Ikonopisov et al. (1970) (1970) . These are: (1) systemic and coronary arterial vasodilation, (2) increase in coronary arterial and venous blood flow, (3) slowing of the heart rate, and (4) increase in pulmonary compliance.
Studies with perhexiline in man have been done in the United States and Brazil (Hirshleifer, 1969;  Martins de Oliveira
